Founded in China in 2009, CanSino Biologics Inc. (CanSinoBIO) is an industry-leading biopharmaceutical company dedicated to providing global solutions for the prevention and treatment of infectious diseases through research & development, manufacturing and commercialization of innovative, high-quality and affordable vaccine products for human use.
CanSinoBIO has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx: 6185.HK) and on the Sci-Tech Innovation Board (STAR Market, SHSE: 688185) of the Shanghai Stock Exchange, making it the first "A+H" dual-listed vaccine company in the history of China's Science and Technology Innovation Board.
Our marketed products include: Convidecia®Air® [Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation], Convidecia® [Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)], Menphecia® [Group A and Group C Meningococcal Conjugate Vaccine (CRM197 Vector)], Menhycia® [Group ACYW135 Meningococcal Conjugate Vaccine (CRM197 Vector)], and Ad5-EBOV. At present, the Company is developing and conducting clinical trials of several products including potential best-in-class and first-in-class vaccines in China and globally innovative and potential global best-in-class vaccines.
CanSinoBIO has developed five key platform technologies, including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant VLP technology, mRNA vaccine technology as well as formulation and delivery technology. In addition, the Company owns a number of core intellectual property rights and proprietary technologies related to vaccine products. CanSinoBIO has established a rich portfolio of a pipeline products preventing more than ten diseases, including COVID-19, Ebola virus disease, tuberculosis, meningitis, pertussis, diphtheria, tetanus, shingles etc., and is participating in innovative R&D collaboration with multiple research institutions across the world.
We have constructed large-scale manufacturing bases in Tianjin and Shanghai, with a floor area of over 100,000 square meters. Both have been designed and constructed, and are operating in accordance with international standards to manufactured multiple novel vaccines. In addition, local filling production lines have been set up in Mexico, Pakistan, and Malaysia to establish joint manufacture. Our full-fledged marketing and supply system that covers China, Southeast Asia, the Middle East, Latin America, and other countries/regions ensures the rapid distribution of vaccine products across the world.
As a leader in innovative vaccine R&D, we are deeply committed to the protection of global public health through the fulfillment of our social and international responsibilities, and the development and supply of high-quality vaccine products.